Risk Analysis of Prostate Cancer in PRACTICAL Consortium - Response by Amin, Al Olama Ali et al.
Risk Analysis of Prostate Cancer in PRACTICAL Consortium—Reply Letter 
Ali Amin Al Olama1, Rosalind A. Eeles 2, 3, Zsofia Kote-Jarai2, Douglas F. Easton1 
1Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, 
University of Cambridge, UK. 2Institute of Cancer Research, London, UK. 3Royal Marsden 
National Health Service (NHS) Foundation Trust, London and Sutton, UK. 
 
Financial Support: D.F. Easton was recipient of the CR-UK grant C1287/A10118. R.A. Eeles 
was recipient of the CR-UK grant C5047/A10692. 
Corresponding Authors: Professor Douglas F. Easton, Centre for Cancer Genetic 
Epidemiology, Department of Public Health and Primary Care, University of Cambridge, UK. 
Email: dfe20@medschl.cam.ac.uk, Telephone: +44 1223 748629, Fax +44 1223 748628; And 
Dr. Ali Amin Al Olama, Centre for Cancer Genetic Epidemiology, Department of Public Health 
and Primary Care, University of Cambridge, UK. Email: aa461@medschl.cam.ac.uk, 
Telephone: +44 1223 748638, Fax +44 1223 748628. 
 
Disclosure of Potential Conflicts of Interest: R.A. Eeles has received speakers bureau 
honoraria from Succinct Communication and medical education support from Janssen. No 
potential conflicts of interest were disclosed by the other authors. 
Word Count: 394 
 
We thank Martens et al. for their comments on our paper. 
We agree that calibration of the model in the extremes of the risk distribution is important. 
We observed (1) , however, that that the estimated odds ratios for men in the top and 
bottom 1% of the risk distribution ( 4.2 and 0.14 respectively) did not in fact differ from 
those predicted under a model with a continuous (log-additive) effect of the PRS on risk (3.8 
and 0.20 respectively). In addition, formal calibration tests showed no evidence of 
departures from the log-additive model (P=0.12 by Hosmer and Lemeshow test). 
In our data, the AUC was 0.63 (95%CI 0.62-0.64) for a model incorporating age and family 
history, and this rose to 0.69 (95%CI 0.68-0.70) when the polygenic risk score was 
incorporated. The AUC cannot, however, be compared directly with other models such as 
the PCPT model, which is based on measurement PSA and DRE and predicts the risk of 
prostate cancer detection on biopsy. Our model is based solely on genetic data and predicts 
the subsequent risk of prostate cancer. Clearly, if PSA level were also incorporated into the 
model, the AUC is likely to be higher. We also note that the AUC is likely to increase as 
additional SNPs are identified. For example, a recent study using data on 65 SNPs estimated 
an AUC of 0.68 (2). Finally, it is worth noting that the AUC is not necessarily a good measure 
of the predictive value of a model, and that other measures such as the net reclassification 
index may be more useful. 
We agree that the discrimination of risk prediction models may be overestimated in the 
dataset in which the model was developed, due to overfitting. To address this, we re-
estimated the model parameters in a random sample of the dataset that included 90% of 
the cases and controls. The polygenic risk score from this model was then tested on the 
remaining 10% of the dataset. The odds ratio per 1 standard deviation of the PRS was 1.74 
(95%CI 1.60-1.79) in the training set and 1.60 (1.49-1.73) in the validation set. Thus, PRS 
remains highly predictive of risk in the validation dataset, but there is some suggestion of 
overfitting. Further validation of polygenic risk scores based on all available SNPs, in 
independent datasets, will be important before such scores can be used routinely. 
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